Work

Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study

Year: 2026

Type: article

Abstract: This is a plain language summary describing results from the Alfa-PROTECT study on safety and efficacy of damoctocog alfa pegol in previously treated children aged between 7 and 12 years with severe haemophilia A. Trial Registration: The Alfa-PROTECT trial is registered at ClinicalTrials.gov: NCT05147662.

Source: European Journal Of Haematology

DOI: 10.1111/ejh.70078

Authors: Margareth C. Ozelo, Matteo Luciani, Heidi Glosli, Kaan Kavakli, Nasrin Samji, Gregory C. Makris, Claudia Tueckmantel, Monika Maas Enriquez, Luciana C. Oliveira, Shveta Gupta, Mario Guillermo Arbesú, Mauro Davoli, Anthony K. C. Chan, Maria Elisa Mancuso

Institutions: Universidade Estadual de Campinas (UNICAMP), Bambino Gesù Children's Hospital, Oslo University Hospital, Ege University, McMaster Children's Hospital, McMaster University, Bayer (Germany), Universidade de São Paulo, Arnold Palmer Hospital for Children, Humanitas University, IRCCS Humanitas Research Hospital

Language: English

Topic: Hemophilia Treatment and Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,650

Funder: Bayer

OpenAlex ID: W7123796537

FWCI:

Cites:

Cited by:

Related to: